CD28 and neoplasm: They found CAR T cells with combined CD28 and 4-1BB co-stimulatory domains and specificity for prostate-specific membrane antigen (PSMA) were superior with regards to cytokine production, in vivo survival and antigen-specific tumor elimination [17].